Business Context and Reporting Period
This Form 8-K Current Report, dated February 21, 2025, pertains to Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX). The filing primarily addresses significant changes in executive leadership, specifically the appointment of a new Chief Financial Officer (CFO) and the departure of the incumbent CFO.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and employment terms.
- New CFO Base Salary: $540,000 annually.
- Target Annual Cash Bonus: 40% of base salary.
- Equity Grant (Expected March 10, 2025): 52,000 Restricted Stock Units (RSUs) and stock options to purchase 80,000 shares.
Material Changes
The filing reports the following material changes in corporate governance and personnel:
- Appointment of CFO: Tobin "Toby" Schilke was appointed as Chief Financial Officer, effective February 28, 2025. He brings over 25 years of biopharma experience, most recently serving as CFO at Revance Therapeutics, Inc.
- Departure of CFO: Marc Wilson is stepping down as Chief Financial Officer, effective February 28, 2025. His resignation is for personal reasons and is not related to any disagreement with the Company regarding operations, policies, or practices.
- Transition Plan: Mr. Wilson will remain with the Company temporarily to assist with the transition of duties to Mr. Schilke.
Guidance, Outlook, and Risks
The filing contains no financial guidance or operational outlook. It includes standard forward-looking statement disclaimers, noting that actual results may differ materially from projections due to risks described in the Company's periodic SEC filings (Form 10-K and 10-Q).
Compensation Contingencies:
- Severance (Standard Termination): If terminated without cause or for good reason, Mr. Schilke is entitled to nine months of base salary, a pro-rata bonus, and nine months of health coverage.
- Severance (Change in Control): If terminated within 12 months of a change in control, benefits increase to 12 months of base salary plus the full target bonus, 12 months of health coverage, and full acceleration of unvested equity awards.
- Clawback Policy: The employment agreement incorporates the Company's Policy for Recovery of Erroneously Awarded Compensation.
Investor Verification Checklist
- Verify the effective date of the CFO transition (February 28, 2025) and the interim leadership structure.
- Confirm the vesting schedule for the 52,000 RSUs and 80,000 stock options expected to be granted on March 10, 2025.
- Review the full text of the Employment Agreement, which will be filed as an exhibit to the Form 10-Q for the quarter ended March 31, 2025.
- Check the Company's most recent Form 10-K and 10-Q filings for updated financial performance data, as this 8-K does not provide revenue or cash flow figures.